Home / Guides by goal / Are Peptides Legal in the US? What FDA and HHS Say
Are Peptides Legal in the US? What FDA and HHS Say
Are peptides legal? It depends on the kind: approved, compounded, research-use-only, supplements. What FDA and HHS have said, with dates.
On this page
“Are peptides legal?” has no single answer, because “peptide” covers an approved drug, a pharmacy-made drug, a dietary supplement and a vial sold as a “research chemical.” This guide sorts them by what FDA and HHS have said about each, with dates. It is not legal advice.
The short answer
It depends on what the product is and how it is made, sold and prescribed. A peptide is a short chain of amino acids, typically 2 to 50 (NHGRI). That says nothing about whether a product is approved, regulated or allowed. FDA and HHS treat these categories differently:
| Category | What FDA or HHS has said | Source |
|---|---|---|
| FDA-approved drugs | FDA approved a specific product for the uses on its label. Approval for one use does not extend to another | FDA |
| Compounded drugs | Not FDA-approved; FDA does not review them for safety, effectiveness or quality before they reach patients. Rules under sections 503A and 503B apply | FDA |
| Six peptides under HHS’s interim policy (Oct. 30, 2026) | HHS said it does not intend to take enforcement action against certain 503A compounding, under conditions. Not approval; creates no rights | Federal Register |
| “Research use only” products | In warning letters, FDA called products of this kind unapproved new drugs where the seller’s website showed they were meant for people | FDA letter |
| Dietary supplements and cosmetics | FDA does not approve either before sale; other rules apply, and what a product claims can change which category it is in | FDA; FDA |
“Not FDA-approved” does not, by itself, answer whether something is legal, and we do not give legal conclusions. For a specific situation, ask a licensed attorney, clinician or pharmacist.
How this guide is built
This is a regulatory explainer, not a ranking. We use FDA’s and HHS’s own words and say when a source is a warning letter (an agency position, not a court ruling) or a law firm’s analysis (a secondary source, and not a legal finding). We checked the status on Nov. 3, 2026, and some of it will change; see “What could change soon.” We do not cover where to buy, how to import, or how to use any peptide.
What about FDA-approved peptide drugs?
Some peptides are approved drugs with an FDA-reviewed label. Examples we cover, each approved for specific uses: semaglutide, tirzepatide, tesamorelin and bremelanotide. Their labels state the approved uses and warnings. Using an approved drug for an unapproved use is called off-label, and FDA’s evaluation of benefits and risks covers the approved use. Whether a particular use is appropriate is a question for a prescriber.
What are compounded peptides?
A compounded drug is made when a licensed pharmacist or physician, or a person supervised by a licensed pharmacist at an outsourcing facility, combines, mixes or alters ingredients. FDA says compounded drugs are not FDA-approved, and describes two sets of rules:
- Section 503A sets the conditions under which compounded products are exempt from FDA approval before marketing, from CGMP requirements and from labeling with adequate directions for use. One condition is a valid patient-specific prescription.
- Section 503B created a voluntary category of compounders called outsourcing facilities, which are subject to CGMP requirements.
For a fuller explanation of these rules, see how 503A compounding works.
For approved drugs there is an additional limit: FDA says a compounder may not make products that are “essentially copies” of a commercially available drug regularly or in inordinate amounts. See what FDA says about compounded GLP-1 drugs.
What did HHS do on Oct. 30, 2026?
HHS published an interim enforcement discretion policy and said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound six peptides under section 503A, if all of the policy’s conditions are met. The covered forms and routes, per the policy:
| Peptide | Form covered | Routes covered |
|---|---|---|
| BPC-157 | acetate | subcutaneous, intramuscular, oral, topical |
| TB-500 | acetate | subcutaneous, intramuscular |
| Epitalon | acetate | subcutaneous, intramuscular, in intermittent courses |
| Semax | free base | intranasal |
| KPV | acetate | topical, oral |
| MOTS-c | acetate | subcutaneous, intramuscular |
The conditions include exact identification of the substance; batch-level testing; an original manufacturer registered with FDA and following CGMP; reporting of adverse events and quality problems; a label stating it is a compounded drug product, not for resale; a single active ingredient; documentation of human oral bioavailability for oral products; a patient-specific prescription; and, for injection, a syringe cleared as a device.
What the policy is not:
- It is not FDA approval. HHS notes FDA does not review compounded drugs.
- It is interim and open to public comment. The docket lists a closing date of 11:59 p.m. Eastern on Nov. 13, 2026.
- It creates no rights. The notice says it “does not establish any rights for any person and is not binding on HHS or the public.” HHS may revisit it.
- It does not add any peptide to FDA’s compounding lists. It applies until a final rule includes or excludes the substances.
- It does not cover outsourcing facilities (503B) or blends of peptides, according to a law-firm analysis (secondary source); the single-ingredient condition is in HHS’s text.
- It does not replace state law, per the same analysis.
Before the policy, all six were on FDA’s “Category 2,” a list of substances FDA said may present significant safety risks for compounding. They left it on April 22, 2026, when the nominations were withdrawn. HHS says neither the placement nor the removal changed their status under section 503A.
Which peptides are not in the policy?
HHS named six. For other peptides we cover, as of Nov. 3, 2026:
- Semaglutide and tirzepatide: approved drugs, not in the policy. FDA proposed not adding them to the 503B list in May 2026.
- Retatrutide: FDA says it cannot be used in compounding under federal law (FDA, Oct. 1, 2026). See our retatrutide guide.
- Tesamorelin: FDA says biological products that moved to licensure in 2020, a list that includes tesamorelin, are not eligible for the 503A and 503B compounding exemptions. We draw no legal conclusion about any product.
- CJC-1295 and ipamorelin: not in the policy. FDA’s advisory committee voted against adding them to the compounding list in 2024. Ipamorelin remains in Category 2 for outsourcing facilities. See our muscle growth guide.
- GHK-Cu: not in the policy. On FDA’s list, non-injectable forms are in Category 1 (under evaluation), and FDA says it intends to consult its advisory committee before the end of February 2027 (FDA list). See our GHK-Cu guide.
FDA’s drug center also proposed in July 2026 not adding any of seven peptides it reviewed to the compounding list, and an advisory committee voted in favor of listing most of them, according to a law-firm account (secondary source). See FDA’s proposal.
What about “research use only” peptides?
FDA’s drug center sent warning letters dated Aug. 24, 2026 to five online sellers of peptide products, calling the products unapproved new drugs (FDA warning letters). In the letters we read, FDA said “research use only” labeling did not change its conclusion, citing evidence on the companies’ websites that the products were meant for people (FDA letter). HHS’s policy describes research-use-only peptides supplied by foreign manufacturers as a safety risk. For GLP-1 products falsely labeled “for research purposes” or “not for human consumption,” FDA urges consumers not to purchase them, and says they are of unknown quality and may be harmful (FDA).
A warning letter states FDA’s position about those companies and facts; it is not a court ruling, and it does not tell you what a buyer’s own legal position is. We do not link to or recommend sellers.
What about supplements and cosmetics?
- Dietary supplements. FDA does not have authority to approve dietary supplements before they are sold. Oral collagen peptides are sold this way. See our collagen peptides guide.
- Cosmetics. The law does not require FDA approval before cosmetics are sold, except for color additives. The line with a drug depends on intended use: FDA says a product intended to “remove wrinkles or increase the skin’s production of collagen” is a drug or a device, not a cosmetic.
What do states say?
State rules are separate from federal ones. Before the policy was issued, boards in Alabama and Mississippi told licensees they may not compound, administer or dispense non-FDA-approved or research-grade peptides. We found no update from them as of Nov. 3, and it isn’t clear how those notices apply to compounding under the HHS policy.
Some details: Mississippi’s statement, from August 2026, came jointly from its nursing, pharmacy and medical licensure boards and speaks to healthcare providers. Alabama’s notice came from its Board of Medical Examiners and is addressed to physicians and certain other practitioners the board oversees. Neither notice names specific peptides. We did not review other states, so this is not a list of where anything is allowed.
Is a peptide banned in sports?
Sport is a separate system. The World Anti-Doping Agency’s 2026 list names BPC-157 as prohibited at all times (class S0), TB-500 in class S2, and tesamorelin in class S2 (WADA 2026 list). Athletes should check with their anti-doping organization.
What could change soon?
- The HHS comment period closes at 11:59 p.m. Eastern on Nov. 13, 2026 (docket). After it closes, the policy remains interim. A law-firm analysis estimates a final rule could take 12 to 24 months (secondary source).
- FDA’s proposal on the 503B list for semaglutide, tirzepatide and liraglutide has no final notice as of Nov. 3, 2026.
- FDA says it intends to consult its advisory committee on GHK-Cu before the end of February 2027 (FDA list).
- State boards may update their notices.
Each of our guides states the date its regulatory status was checked.
What should you ask your doctor or pharmacist?
- Is there an FDA-approved product that fits my situation, and what are the uses on its label?
- If a compounded product is suggested, who makes it, and does it meet the conditions that apply to it (identity, testing, labeling, a patient-specific prescription)?
- Does my state’s licensing board have a notice that affects this?
- Do I compete in a tested sport?
We do not give doses, and we do not recommend products, pharmacies or sellers.
Frequently asked questions
Are peptides legal in the US?
It depends on the product. Approved peptide drugs have an FDA label. Compounded peptides are not FDA-approved and are subject to conditions. Products sold as “research use only” have drawn FDA warning letters. We do not give legal conclusions.
Is BPC-157 legal?
BPC-157 is not FDA-approved. On Oct. 30, 2026, HHS said it does not intend to take enforcement action against certain compounding of BPC-157 acetate, under conditions, on an interim basis. That is not an approval and not a legalization. State notices are separate.
Can you buy research peptides?
We do not cover buying. FDA has called products of this kind unapproved new drugs where the seller’s evidence showed intended human use, and urges consumers not to purchase GLP-1 products falsely labeled for research purposes.
Is compounded semaglutide legal?
FDA has set conditions and taken enforcement positions, which we describe in our guide to compounded GLP-1 drugs. We do not call it legal or illegal in general.
Does “not FDA-approved” mean illegal?
No single answer. It means FDA has not approved the product. The rules differ for a supplement, a cosmetic, a compounded drug and an investigational drug.
From Best Peptides Today
Sources we checked
- Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed .
- HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed .
- Regulations.gov docket HHS-OASH-2026-0496Other. Accessed .
- Frier Levitt analysis of the HHS policy (secondary source)Other. Accessed .
- McDermott+: PCAC votes on peptides (secondary source)Other. Accessed .
- FDA: compounding laws and policiesFDA. Accessed .
- FDA: bulk drug substances that may present significant safety risks (Category 2)FDA. Accessed .
- FDA 503A Category 1 list (updated May 14, 2026)FDA. Accessed .
- FDA CDER proposal on seven peptides (July 2026)FDA. Accessed .
- FDA: notice to compounders on changes that affect compounding, March 23, 2020FDA. Accessed .
- FDA's concerns with unapproved GLP-1 drugs used for weight loss (Oct. 1, 2026)FDA. Accessed .
- FDA warning letter, Aug. 24, 2026 (research-use-only peptide products)FDA. Accessed .
- FDA: understanding unapproved use of approved drugs ("off label")FDA. Accessed .
- FDA: questions and answers on dietary supplementsFDA. Accessed .
- FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulatedFDA. Accessed .
- FDA: wrinkle treatments and other anti-aging productsFDA. Accessed .
- Alabama Board of Medical Examiners: notice on prescribing non-FDA-approved research-grade peptidesOther. Accessed .
- Mississippi nursing, pharmacy and medical licensure boards: joint statement on peptides (Aug. 19, 2026)Other. Accessed .
- WADA 2026 Prohibited ListOther. Accessed .
- NHGRI Talking Glossary: peptideOther. Accessed .
- FDA warning letters indexFDA. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.